Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Trump Media and Technology Group Corp (DJT) vs GSK plc (GSK) Price & Performance

Trump Media and Technology Group CorpTrade

Price performance (Past 24H)

Key statistics

Trump Media and Technology Group Corp vs GSK plc — how do they compare? Trump Media and Technology Group Corp trades at $8.12 (market cap $2.28B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 40.3× Trump Media and Technology Group Corp's market cap, and GSK plc pays a 3.9% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and GSK plc for 93 Days on average.

DJTGSK
Market Cap
$2.28B$91.88B
Volume
3,148,3797,730,529
Sector
MediaHealth
52-Week High
$17.07$61.18
52-Week Low
$7.06$43.24
Typical Hold Time
17 Days93 Days
Enterprise Value
$2.35B$111.88B
Dividend Yield
—3.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Trump Media and Technology Group Corp

DJT trades at $8.125, down 1.16% with a bearish technical signal. The company shows minimal revenue of $3.68M against massive losses of -$712M, resulting in a negative net margin of -28,860%. Cash flow trends reveal heavy investing outflows, while a proposed merger with TAE Technologies aims to pivot toward fusion energy development. The stock faces significant fundamental challenges despite oversold RSI indicators.

Outlook remains highly speculative with substantial execution risks. The merger could provide long-term upside if fusion technology commercializes, but current financials and negative profitability signal extreme caution. Investors face dilution risk and cash burn with no near-term profit visibility.

GSK plc

GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.

GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DJT

No sentiment data available yet.

GSK
100% Buy0% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About Trump Media and Technology Group Corp

Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.

Read more on DJT →

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK →